DOCTOR OF PHARMACY
Fifth Year Pharm. D. : SUMMER : 2022
SUBJECT: PHARMACOEPIDEMIOLOGY & PHARMACOECONOMICS

Day : Friday   Time : 10:00 AM-01:00 PM
Date 06-May-2022   S-5750-2022   Max. Marks: 70

N.B. :

1) **Q. No. 1** and **Q. No. 5** are **COMPULSORY**. Out of remaining questions, attempt **ANY TWO** questions from **each** section.
2) Figures to the right indicate **FULL** marks.
3) Answer to both section should be written in the **SEPARATE** answer books.

SECTION - I

Q.1 **A)** Answer **ANY FOUR** of the following: (08)
    a) Write the limitations of case-control studies.
    b) State any two applications of Pharmacoepidemiology?
    c) Define Meta-analysis.
    d) Enumerate various automated data base systems.
    e) Enlist the steps involved in establishing drug utilization review (DUR) in a hospital.
    f) Mention any two advantages of prescription event monitoring (PEM).

    B) Enumerate the demerits of spontaneous reporting system.   (03)

Q.2 What are the various study designs used in pharmacoepidemiological research? Explain any two in detail.   (12)

Q.3 **a)** Explain cross sectional study with suitable example.   (07)
    b) What are various methods to improve patient medication adherence reported in pharmacoepidemiological studies?   (05)

Q.4 Write short notes on **ANY THREE** of the following: (12)
    a) Methods of measuring risks.
    b) National Pharmacovigilance program of India.
    c) Time-Risk relationship with suitable example.
    d) Record Linkage System
    e) Defined Daily Dose (DDD)

SECTION - II

Q.5 **A)** Answer **ANY FOUR** of the following: (08)
    a) State any two applications of pharmocoeconomics.
    b) If intervention A allows a patient to live 3 additional year with 0.6 quality of life, then intervention A provides how much QALYs to the patient?
    c) State two applications of Cost Utility Analysis (CUA).
    d) What is a case report? Provide an example.
    e) "There is a need of pharmocoepidemiology". Write any two needs.
    f) What is an incidence? State an example.

    B) What are the ways to measure and report prevalence depending on the timeframe of the estimate?   (03)

Q.6 Write in detail the basics of cost benefit analysis (CBA) in pharmacoeconomics.   (12)

Q.7 **a)** What is Standard Gamble method? How it is interpreted?   (07)
    b) Write the salient features of Cost Minimization Analysis (CMA).   (05)

Q.8 Write short notes on **ANY THREE** of the following: (12)
    a) Clinical problems to be addressed by pharmacoepidemiologic research in drug induced birth defects
    b) Discounting in pharmacoeconomics
    c) Health Related Quality of Life (HRQoL)
    d) Registries
    e) Study designs used to analyze vaccine safety

*   *   *   *   *